JPRN-UMIN000014707已完成2 期
Efficacy and safety of neoadjuvant chemotherapy by S-1 plus cisplatin for Stage III esophageal squamous cell carcinoma: A phase II trial - Neoadjuvant chemotherapy by S-1 plus cisplatin for esophageal squamous cell carcinoma
agoya University Hospital0 个研究点目标入组 30 人开始时间: 2014年7月30日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Synchronous or metachronous (within 5 years) malignancies other than carcinoma in situ 2) Uncontrolled infection 3) Pregnant women, possibly pregnant women, wishing to become pregnant, and nursing mothers 4) Psychiatric disease 5) Continuous systemic steroid therapy 6) Uncontrolled severe complications (DM, hypertension, diarrhea, et al.) 7) Patient with symptomatic cardiovascular disease or asymptomatic disease but have been treated 8) Symptomatic CNS metastasis 9) Interstitial lung disease or pulmonary fibrosis 10) Hypersensitivity for S-1 or cisplatin 11) Flucytosine, phenytoin, warfarin potassium or aminoglycoside antibiotic administration 12) Intestinal bleeding 13) Judged by physician inadequate for inclusion in this trial
研究者
相似试验
进行中（未招募）
3 期
Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial)cholangiocarcinomamuscle invasive gallbladder carcinomaCancer - Biliary tree (gall bladder and bile duct)ACTRN12615001283561Australasian Gastro-Intestinal Trials Group32
招募中
不适用
Prospective study of neoadjuvant chemotherapy with FEC100x4 for BRCAness cases in triple negative breast cancerBreast cancerJPRN-UMIN000029433Tokyo medical university70
已完成
不适用
Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility multicenter study(1) breast cancer with histological confirmation(2) stage II or III breast cancer and previous standard anthracycline and/or taxane-based PSC, followed by curative surgery(3) age 20-75 years(4) Eastern Cooperative Oncology Group performance status 0,1(5) adequate gastrointestinal function(6) adequate organ functionJPRN-UMIN000013469Saitama Medical University International Medical Center40
招募中
2 期
eoadjuvant chemotherapy in NSCLCCTRI/2016/05/006916investigator initiated study
已完成
不适用
Prospective study of neoadjuvant chemotherapy for HER2 positive breast cancer.JPRN-UMIN000046338Sapporo Medical University24